Resideo
REZI
$19.59
-4.49%
Resideo Technologies is an industrial technology and distribution company that manufactures and sells sensing and control products — including HVAC controls, smoke and carbon monoxide detectors, fire suppression and security equipment — for residential and commercial buildings, while also operating a large wholesale distribution arm (ADI) serving the security and low-voltage trade. The company occupies a hybrid position in the Industrials sector: a branded, installed-base-driven products business (Honeywell Home heritage) bolted onto a scale distribution platform, giving it both OEM margin exposure and distribution-channel breadth that few pure-play peers replicate. The current investor narrative is dominated by the announced ADI spin-off and the resulting portfolio simplification debate, with bulls (notably Alta Fox, which disclosed a roughly $44 million stake equal to ~10% of its reported AUM in February 2026) arguing for sum-of-the-parts value and margin expansion, while bears point to weak full-year guidance that triggered a ~21% single-day collapse in August 2026. Sentiment has been further complicated by a sharp de-rating through the summer and fall, leaving the stock down more than 55% over the past year even as management executes on separation and buyback activity.…
REZI
Resideo
$19.59
Related headlines
Investment Opinion: Should I buy REZI Today?
Rating: Hold, with a speculative accumulation bias only for risk-tolerant investors. The core thesis is that Resideo trades at 0.487x trailing sales — below even its own prior multi-year trough of ~1.04x — because the market has lost confidence in guidance after the August 2026 cut, while five of six analysts still rate the stock Buy with a $29.83 average target implying roughly +55% upside from $19.24. The gap between a 9.36x forward PE on $1.92 estimated EPS and a -6.48x trailing PE is the entire investment debate: you are being paid a distressed multiple to underwrite an earnings normalization and an ADI separation that have not yet been reported.
Supporting evidence is real but prospective. Q2 2026 delivered $97 million of net income (4.90% net margin), 30.04% gross margin versus 27.20% in Q1 2026, $148 million of operating cash flow and $119 million of free cash flow — a genuine sequential inflection from the -$825 million Q2 2025 loss driven by a ~$917 million other-expense charge. The Products segment contributed $1.401 billion of the $1.981 billion Q2 revenue (~71%), giving the separation a higher-margin core to stand on, and the $949 million cash balance with a 1.913x current ratio covers near-term liquidity. But revenue grew only 1.96% YoY, TTM free cash flow is -$1.399 billion, debt-to-equity is 1.105x, and the $29.83 consensus target sits essentially at the $29.89 52-week high — suggesting the Street has not fully marked models to post-cut reality, which is why the target range spans $20 to $45.
Three risks could invalidate the thesis: a second guidance cut that breaks the $1.92 EPS assumption, a separation that crystallizes a low-margin distribution business rather than unlocking sum-of-parts value, and margin compression in the 27.2%-30.0% gross margin band that has held for six quarters. This Hold would upgrade to Buy on a full quarter of post-separation results with reaffirmed guidance and gross margin holding at or above 30%, or if the stock holds the $15.90-$16.21 support zone while the 1-month relative strength (+6.84 points versus SPY) extends; it would downgrade to Sell on a break below $15.90 or FY revenue guidance below the $3.14 billion consensus. Verdict: undervalued relative to its own history and to industrial distribution peers on sales, but fairly-to-appropriately discounted given execution risk — a value opportunity that requires confirmation, not a clean bargain.
Sign up to view all
REZI 12-Month Price Forecast
The setup is a deeply de-rated industrial trading at 0.487x sales with a 9.36x forward PE that only works if the $1.92 EPS estimate materializes, and the evidence for that is one improving quarter rather than a trend. The bull case is anchored by the ADI separation, Alta Fox's ~$44 million stake (~10% of reported AUM), and a sell-side consensus that has not capitulated — Morgan Stanley reiterated Overweight in July 2026 and Oppenheimer sits at Outperform — while the bear case is anchored by the August guidance cut, -$1.399 billion TTM free cash flow, and a 55.02% trailing-year decline. With a 1.555 beta and 4.41 short ratio, the distribution of outcomes is wide, which is why I weight the base case at 50% and split the tails evenly at 25% each. I would upgrade to bullish on a full quarter of post-separation results with reaffirmed guidance and gross margin at or above 30%, and downgrade to bearish on a break below $15.90 or FY revenue guidance below the $3.14 billion consensus.
Wall Street consensus
Coverage is thin but tilts bullish: six analysts cover the stock with a 5 Buy / 1 Hold / 0 Sell distribution, and the average target price of $29.83 implies roughly +55% upside from the current $19.24. That is an unusually large implied return for a consensus target and reflects how far the stock has fallen below where analysts' models sit — the average target is essentially at the 52-week high of $29.89, suggesting the Street has not fully marked estimates to the post-guidance-cut reality. The consensus leans clearly bullish on ratings but the target dispersion tells a more cautious story.
The full target range runs from $20.00 to $45.00 — a 125% spread between low and high, which signals very low conviction and high uncertainty rather than a tight, well-anchored view. The $45 high target implicitly assumes successful execution of the ADI separation, multiple re-rating toward historical PS levels, and delivery on the $1.92 EPS estimate; the $20 low target is barely above spot and effectively prices in continued margin compression and no re-rating. Institutional ratings show Morgan Stanley maintaining Overweight (reiterated July 13, 2026, after upgrading from Equal Weight in August 2025) and Oppenheimer at Outperform, while JP Morgan sits at Neutral — a pattern of stable-to-improving sell-side sentiment that has not yet been validated by price action. With only six analysts and a 4.41 short ratio indicating meaningful short interest, the setup is one where a positive catalyst (separation completion, guidance stabilization) could force a sharp squeeze, but the wide target spread means position sizing should reflect genuine two-sided risk.
Bulls vs Bears: REZI Investment Factors
The bear case currently has stronger evidence: revenue growth of just 1.96% YoY, negative trailing EPS of -$0.14, TTM free cash flow of -$1.399 billion, and a guidance cut that vaporized ~21% of market value in a single session are hard, reported facts, whereas the bull case rests on a separation that has not yet closed and a $1.92 forward EPS estimate that has not yet appeared in results. The bull side is not empty — 0.487x sales is below even the prior 1.04x trough, five of six analysts rate Buy with a $29.83 average target (+55%), and Q2 2026 profitability ($97 million net income, 30.04% gross margin, $119 million FCF) genuinely improved sequentially — but these are prospective and conditional rather than demonstrated. The single most important tension is whether the ADI separation unlocks sum-of-the-parts value and margin expansion, or whether it simply crystallizes a lower-margin distribution business at a time when the products segment is growing at low single digits; if separation completes cleanly and guidance stabilizes, the 0.487x sales multiple re-rates sharply, but if distribution margins compress further the stock is a value trap at any multiple. Until the market sees a full quarter of post-separation results and reaffirmed guidance, the weight of evidence favors caution over pre-emptive accumulation.
Bullish
- Deep discount to sales and peers: At $19.24 the stock trades at just 0.487x trailing sales and 0.883x EV/Sales, versus the roughly 1.0x-1.5x sales typical of industrial distribution and building-products peers — a discount of 50% or more. Resideo's own PS ratio has ranged from ~1.04x (Q1 2025) to 2.30x (Q3 2025), so the current multiple sits below even the prior multi-year trough, implying the market has priced in a broken earnings model.
- Analyst consensus implies 55% upside: Five of six covering analysts rate the stock Buy (one Hold, zero Sell), and the $29.83 average target implies roughly +55% from spot — essentially at the 52-week high of $29.89. Morgan Stanley reiterated Overweight in July 2026 and Oppenheimer sits at Outperform, suggesting sell-side conviction has not broken even as the price has.
- ADI spin-off could unlock sum-of-parts: Alta Fox disclosed a ~$44 million stake equal to ~10% of reported AUM in February 2026, explicitly betting on margin expansion and business separation. With ~71% of Q2 revenue ($1.401 billion of $1.981 billion) coming from the higher-margin Products segment, separating the lower-margin ADI distribution arm could allow each piece to be valued on its own merits rather than at a blended distressed multiple.
- Profitability inflecting off the trough: Q2 2026 net income of $97 million (4.90% net margin) and 30.04% gross margin marked a clear improvement from Q1 2026's $38 million and 27.20% gross margin, and a dramatic swing from the -$825 million loss in Q2 2025 driven by a ~$917 million other-expense charge. Q2 2026 also generated $148 million of operating cash flow and $119 million of free cash flow, showing the core business can self-fund.
Bearish
- Guidance cut triggered 21% collapse: The August 2026 full-year guidance cut overshadowed a Q2 earnings beat and drove a ~21% single-day drop, with the stock gapping from $36.23 on August 3 to $26.17 on August 4 and then to $20.46 by August 13. That is a management credibility event, not just a sentiment wobble — the market has stopped trusting forward guidance.
- Revenue growth is decelerating to stall speed: Q2 2026 revenue of $1.981 billion grew only 1.96% year-over-year, following $1.912 billion in Q1 2026 and $1.895 billion in Q4 2025 — essentially flat-to-low-single-digit growth. Consensus FY revenue of ~$3.14 billion against a $3.64 billion market cap means the market is paying almost nothing for growth, and the guidance reset suggests management sees no near-term acceleration.
- Negative trailing earnings and cash flow: Trailing EPS is -$0.14 with a trailing PE of -6.48x, trailing net margin of -7.05%, and ROE of -18.07%. Free cash flow TTM is -$1.399 billion, driven by the Q3 2025 operating cash outflow of -$1.571 billion (a -$1.783 billion working capital swing tied to the ADI separation), leaving the PCF ratio at -3.20 and the FCF yield effectively negative.
- Leverage and thin margins leave little cushion: Debt-to-equity of 1.105x is elevated for an industrial, and gross margin has hovered in a narrow 27.2%-30.0% band over the last six quarters with a 6.61% operating margin. The company repaid $396 million of debt in Q2 2026, consuming cash, and the $1.92 forward EPS estimate requires margins to hold at recent levels — a low-conviction assumption against 1.96% revenue growth.
REZI Technical Analysis
Resideo is in a pronounced, sustained downtrend that has only recently begun to stabilize. The stock is down 55.02% over the trailing year and 45.28% year-to-date, and at $19.24 it sits at roughly 23.9% of its 52-week range of $15.90 to $29.89 — deep in the lower quartile of the band, a positioning that historically signals either capitulation value or a falling knife rather than momentum. The max drawdown of -63.57% confirms the severity of the de-rating, and the fact that the 52-week high ($29.89) is now more than 55% above spot underscores how much technical damage has accumulated.
Short-term momentum, however, has turned constructive and is diverging sharply from the longer-term trend. The stock is up 4.85% over the past month versus a -1.99% decline in SPY, producing a relative strength of +6.84 points, while the 3-month change of -26.68% and 6-month change of -52.26% show the damage was concentrated in the May–August window (including the August 4 gap from $36.23 to $26.17 and the August 13 drop to $20.46). This 1-month-versus-1-year divergence — positive near-term drift against a deeply negative annual trend — is characteristic of a bottoming attempt or mean-reversion bounce rather than a confirmed reversal, and it needs follow-through above the $20–21 area to be credible.
Key technical levels are well defined. Support sits at the 52-week low of $15.90, with the October 14 close of $16.21 acting as a secondary floor; a breakdown below $15.90 would signal fresh distribution and likely open a new leg lower. Resistance is anchored at the 52-week high of $29.89, with intermediate supply in the $20.50–$21.50 zone (the August consolidation shelf) and the $24–$26 gap area above that. With a beta of 1.555, the stock is roughly 55% more volatile than the market, meaning position sizing should be scaled down accordingly and stops placed with wider bands — a 1.5 beta name can move 7–8% on a single market-wide risk-off day, which materially raises the cost of being early on a turnaround thesis.
Beta
—
—
Max Drawdown
-63.6%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-52.3%
Cumulative gain past year
| Period | REZI Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | -5.9% |
| 3m | -24.9% | -5.2% |
| 6m | -50.7% | -0.6% |
| 1y | -52.3% | +8.2% |
| ytd | -44.3% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
REZI Fundamental Analysis
Revenue is growing but only modestly, and the trajectory is decelerating rather than accelerating. Q2 2026 (quarter ended July 4, 2026) revenue was $1.981 billion, up just 1.96% year-over-year, following $1.912 billion in Q1 2026 and $1.895 billion in Q4 2025 — a run-rate that is essentially flat-to-low-single-digit growth. The Products and Solutions segment contributed $1.401 billion of the Q2 total, meaning roughly 71% of revenue comes from the products business with the balance from distribution. The tepid top line is the crux of the bear case: with consensus FY revenue estimates of ~$3.14 billion against a $3.64 billion market cap, the market is not paying for growth, and the August guidance cut suggests management sees limited near-term acceleration.
Profitability is positive but volatile and structurally thin. Q2 2026 net income was $97 million on a 4.90% net margin, with gross margin of 30.04% and operating margin of 6.61% — a meaningful improvement from Q1 2026's $38 million net income and 27.20% gross margin, and a dramatic swing from the Q2 2025 loss of -$825 million (a -42.46% net margin quarter driven by a ~$917 million other-expense charge). Gross margin has hovered in a narrow 27.2%–30.0% band over the last six quarters, which is typical for industrial distribution but leaves little cushion; the trailing net margin of -7.05% and negative trailing EPS of -$0.14 reflect the prior-year impairment rather than current run-rate economics, and the forward EPS estimate of $1.92 implies the Street expects the recent quarterly profitability to persist.
Balance sheet and cash flow are the weakest part of the story. Debt-to-equity stands at 1.105x with a current ratio of 1.913x, so liquidity is adequate but leverage is elevated for an industrial. Free cash flow TTM is -$1.399 billion, driven by the Q3 2025 operating cash outflow of -$1.571 billion (a -$1.783 billion working capital swing tied to the ADI separation), and ROE is -18.07% on a trailing basis versus ROA of +4.60%. The more recent quarters are better — Q2 2026 generated $148 million of operating cash flow and $119 million of free cash flow with $949 million of cash on the balance sheet — but the company also repaid $396 million of debt in the quarter, and the PCF ratio of -3.20 and FCF yield that is effectively negative on a TTM basis mean the company is not yet self-funding at a level that supports aggressive capital returns.
Quarterly Revenue
$2.0B
2026-07
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
30.0%
Latest Quarter
Free Cash Flow
$-1.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is REZI Overvalued?
Because trailing net income is negative (EPS of -$0.14, trailing PE of -6.48x), the PE ratio is not a valid primary metric; I am leading with the price-to-sales ratio of 0.487x and cross-checking against EV/Sales of 0.883x. The forward PE of 9.36x against a trailing PE of -6.48x is a stark gap that reflects the market pricing a full normalization of earnings to the $1.92 consensus EPS estimate — essentially, investors are being asked to underwrite a recovery that has not yet appeared in reported results, which is why the stock trades at a distressed multiple rather than a growth multiple.
On a peer basis, the 0.487x PS and 0.883x EV/Sales are well below what industrial distribution and building-products peers typically command (often 1.0x–1.5x sales), implying a discount of roughly 50% or more to the sector on sales. The 1.25x price-to-book is closer to fair for a low-ROE industrial, and the 9.36x forward PE is cheap in absolute terms but only if the $1.92 EPS estimate holds — against a 6.61% operating margin and 1.105x leverage, that is not a high-conviction assumption. The discount looks less like a mispricing and more like compensation for execution risk around the ADI spin-off and the guidance reset.
Historically, Resideo's own PS ratio has ranged from roughly 1.04x (Q1 2025) to 2.30x (Q3 2025), and its PE has traded between roughly 5.8x and 50x depending on the earnings base. At 0.487x sales, the stock is at the very bottom of its multi-year valuation band — below even the 1.04x trough — which means the market is pricing in either significant fundamental deterioration or a broken earnings model. That can be a genuine value opportunity if the separation unlocks margin expansion, but it can equally be a value trap if distribution margins compress further; the historical context argues for patience and confirmation rather than pre-emptive accumulation.
PE
-6.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~20x
vs. Industry Avg
29.2x
Industry PE ~29.2x*
EV/EBITDA
-49.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are concentrated in cash generation and leverage. TTM free cash flow is -$1.399 billion, driven by the Q3 2025 operating cash outflow of -$1.571 billion from a -$1.783 billion working capital swing tied to the ADI separation, and the PCF ratio of -3.20 confirms the company is not self-funding on a trailing basis. Debt-to-equity of 1.105x is elevated for an industrial, and the company repaid $396 million of debt in Q2 2026 even as it held $949 million of cash, while gross margin has been pinned in a narrow 27.2%-30.0% band for six quarters with a 6.61% operating margin — leaving almost no cushion if distribution volumes soften. The forward EPS estimate of $1.92 versus trailing EPS of -$0.14 means the entire valuation depends on a normalization that has not yet been reported, and revenue growth of just 1.96% YoY provides little operating leverage to deliver it.
Market and competitive risks center on valuation compression and execution credibility. At 0.487x PS the stock is already at the bottom of its multi-year band (versus a 1.04x-2.30x historical range), so the risk is less multiple compression than a value trap: if the ADI separation fails to unlock sum-of-parts value, the discount persists or widens. The August 2026 guidance cut that drove a ~21% single-day collapse and the gap from $36.23 to $26.17 shows how violently the market punishes guidance misses, and with a beta of 1.555 the stock amplifies any sector rotation out of Industrials or macro risk-off move. Competitive pressure in HVAC controls and security distribution, plus the structural shift toward connected-home platforms, threatens the installed-base moat that underpins the Products segment's ~71% revenue share.
The worst-case scenario is a failed or value-destructive separation combined with a second guidance cut: ADI distribution margins compress, the $1.92 EPS estimate is marked down, and the stock retests its 52-week low of $15.90. From the current $19.24 that is roughly -17% to the 52-week low, and the October 14 close of $16.21 acts as a secondary floor on the way down; a breakdown below $15.90 would signal fresh distribution and open a new leg lower toward the analyst low target of $20.00 being breached. The historical max drawdown of -63.57% shows how far this name can fall in a bad cycle, and with a 1.555 beta and 4.41 short ratio, the downside can arrive quickly — a realistic adverse case is -17% to -25% (to $15.90-$14.50) within twelve months if separation execution disappoints.
FAQ
Ranked by severity: first, execution and credibility risk — the August 2026 guidance cut erased ~21% of market value in a single session (from $36.23 to $26.17), and a second cut would mark down the $1.92 EPS estimate that the entire 9.36x forward multiple depends on. Second, financial risk — TTM free cash flow of -$1.399 billion from a -$1.783 billion working capital swing, debt-to-equity of 1.105x, and a gross margin pinned in a 27.2%-30.0% band for six quarters leave little cushion. Third, separation risk — if the ADI spin crystallizes a lower-margin distribution business instead of unlocking sum-of-parts value, the stock is a value trap at any multiple. Fourth, market risk — a 1.555 beta means it is ~55% more volatile than the market, so a sector rotation out of Industrials or a risk-off day can move it 7-8%, and the 4.41 short ratio amplifies moves in both directions.
The base case carries 50% probability with a $20.00-$29.83 range: the separation proceeds, the multiple stays depressed near 0.5x-0.7x sales, and the stock grinds from $19.24 toward the $20.50-$21.50 August shelf with the $29.83 average target acting as a ceiling until guidance is re-established. The bull case (25%) targets $29.83-$45.00 on a clean spin, reaffirmed guidance, gross margin at or above 30%, and short covering into thin six-analyst coverage. The bear case (25%) targets $15.90-$20.00 on a second guidance cut or a value-destructive separation, with the $20.00 analyst low becoming the top of the range. The base case is most likely because it assumes only what is already observable — one improving quarter and a pending separation — rather than requiring new evidence.
On sales, REZI screens clearly undervalued: 0.487x PS and 0.883x EV/Sales versus the roughly 1.0x-1.5x typical of industrial distribution peers, and below its own historical range of ~1.04x (Q1 2025) to 2.30x (Q3 2025). The 1.25x price-to-book is closer to fair for a low-ROE industrial, and the 9.36x forward PE looks cheap in absolute terms. But trailing PE of -6.48x and PCF of -3.20 are not meaningful because trailing earnings and cash flow are negative. The market is effectively pricing a broken earnings model — it expects the $1.92 forward EPS to be delivered and the separation to unlock value, and it is charging a discount for the risk that neither happens. That is a discount for execution risk, not a clean mispricing.
The risk/reward is asymmetric but conditional. Upside to the $29.83 average analyst target is roughly +55% from $19.24, and the $45 high target implies more than +130% if the ADI separation unlocks sum-of-parts value and the $1.92 EPS estimate is delivered, while the $20.00 low target sits barely above spot. Downside is bounded near the $15.90 52-week low, roughly -17%, though the -63.57% historical max drawdown shows how far this name can fall in a bad cycle. The catch is that the bull case rests on a separation that has not closed and earnings that have not been reported, against hard facts of 1.96% revenue growth and -$1.399 billion TTM free cash flow. It is a reasonable speculative buy only for risk-tolerant investors who size positions for a 1.555 beta and can wait for a full post-separation quarter; for most others, waiting for confirmation is the better trade.
This is a medium-term special-situation holding, not a short-term trading vehicle and not a passive long-term compounder. The catalyst path — ADI separation completion, a full quarter of post-separation results, and guidance re-establishment — plays out over roughly 12-24 months, which argues for a minimum holding period of about 12 months to let the thesis be tested. Short-term trading is treacherous: a 1.555 beta, a 4.41 short ratio, and a -63.57% max drawdown mean single-day moves of 7-8% are routine, and the stock has already shown it can gap 21% on one guidance release. The 0.96% dividend yield with a negative payout ratio offers no income support, and earnings visibility is low with only six analysts covering. Position sizing should reflect genuine two-sided risk rather than a buy-and-forget allocation.